Inhibrx Biosciences, Inc. INBX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s accrued expenses?
- Inhibrx Biosciences, Inc. (INBX) reported accrued expenses of $2.24M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s accrued expenses changed year-over-year?
- Inhibrx Biosciences, Inc.'s accrued expenses decreased by 17.5% year-over-year, from $2.72M to $2.24M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s accrued expenses?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s accrued expenses has grown at a -58.5% compound annual growth rate (CAGR), from $43.3M to $7.45M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.